公告显示，截至公告披露日，楼国梁合计持有公司股份712.02万股，占公司总股本股的3.0882%。 北京商报讯（记者 丁宁）2月12日晚间，昊海生科（688366）发布公告称，公司股东楼国梁因自身资金 需要，计划自公告披露之日起3个交易日后3个月内，通过集中竞价和大宗交易方式合计减持不超过100 万股的公司股份，占公司总股本的比例不超过0.4337%。 ...

证券代码：688366 证券简称：昊海生科 公告编号：2026-001 上海昊海生物科技股份有限公司 减持计划的主要内容：楼国梁先生因自身资金需要，计划自本公告披露 之日起 3 个交易日后 3 个月内，通过集中竞价和大宗交易方式合计减持不超过 1,000,000 股的公司股份，占公司总股本 230,561,595 股的比例不超过 0.4337%， 其中，通过集中竞价方式减持不超过 1,000,000 股，通过大宗交易方式减持不超 过 1,000,000 股。减持价格将根据二级市场价格确定。 楼国梁先生于 2021 年 7 月 7 日起不再为公司 5%以上的股东，本次减持 股份计划系基于楼国梁先生于公司在上海证券交易所科创板上市时的公开承诺 所作出。 | 股东名称 | 楼国梁 | | | | --- | --- | --- | --- | | | 控股股东、实控人及一致行动人 | □是 | √否 | | 股东身份 | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | 一、减持主体的基本情况 1 | | 其他：5%以下股东 | | --- | --- | | ...

（记者 王晓波） 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 每经AI快讯，昊海生科2月12日晚间发布公告称，截至本公告披露日，楼国梁先生合计持有上海昊海生 物科技股份有限公司股份约712万股，占公司总股本约2.31亿股的3.0882%。相关股份来源于公司首次公 开发行前以及上市后公司实施资本公积金转增股本取得的股份，其中，首次公开发行前股份已于2020年 10月30日解除限售并上市流通，资本公积金转增股本取得的股份于2024年6月20日上市流通。 楼国梁先生因自身资金需要，计划自本公告披露之日起3个交易日后3个月内，通过集中竞价和大宗交易 方式合计减持不超过100万股的公司股份，占公司总股本约2.31亿股的比例不超过0.4337%，其中，通过 集中竞价方式减持不超过100万股，通过大宗交易方式减持不超过100万股。减持价格将根据二级市场价 格确定。 ...

Core Insights - Tencent Holdings (00700), Southern Hang Seng Technology (03033), and Xiaomi Group-W (01810) ranked as the top three in net inflow of southbound funds, with net inflows of 1.792 billion, 0.571 billion, and 0.412 billion respectively [1] - The top three in net outflow of southbound funds were Yingfu Fund (02800), Hang Seng China Enterprises (02828), and Kuaishou-W (01024), with net outflows of -4.553 billion, -1.380 billion, and -0.576 billion respectively [1] - In terms of net inflow ratio, Huaxia Hang Seng Technology (03088), Southern East Selection (03441), and Anhui Wantuo Expressway (00995) led the market with ratios of 90.53%, 74.02%, and 68.27% respectively [1] - The top three in net outflow ratio were Southern Hong Kong Stock Connect (03432), Fuyao Glass (06865), and Baize Medical (02609) with ratios of -100.00%, -59.27%, and -53.09% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.792 billion, representing a 12.21% increase, closing at 560.000 (+2.28%) [2] - Southern Hang Seng Technology (03033) saw a net inflow of 0.571 billion, with a 6.77% increase, closing at 5.300 (+1.34%) [2] - Xiaomi Group-W (01810) recorded a net inflow of 0.412 billion, with a 9.45% increase, closing at 35.200 (+0.06%) [2] Net Outflow Rankings - Yingfu Fund (02800) experienced the highest net outflow of -4.553 billion, with a -22.13% decrease, closing at 27.220 (+1.72%) [2] - Hang Seng China Enterprises (02828) had a net outflow of -1.380 billion, representing an -11.37% decrease, closing at 93.940 (+1.56%) [2] - Kuaishou-W (01024) faced a net outflow of -0.576 billion, with a -10.25% decrease, closing at 69.300 (-2.74%) [2] Net Inflow Ratio Rankings - Huaxia Hang Seng Technology (03088) led with a net inflow ratio of 90.53%, with a net inflow of 47.6883 million, closing at 6.875 (+1.33%) [3] - Southern East Selection (03441) followed with a net inflow ratio of 74.02%, with a net inflow of 18.0421 million, closing at 11.600 (+1.13%) [3] - Anhui Wantuo Expressway (00995) had a net inflow ratio of 68.27%, with a net inflow of 5.6553 million, closing at 13.340 (-0.07%) [3]

Core Viewpoint - The company focuses on rapidly developing treatment areas such as medical aesthetics, wound care, ophthalmology, orthopedics, and surgery, accelerating the transformation of innovative results [2] Group 1: Product Development - The company has received approvals for high-end hyaluronic acid products "Haimi" and "Haimi Moon White," as well as various mid-range and high-end artificial lenses and high-permeability corneal shaping lenses [2] - The company is expanding its product line in medical aesthetics and ophthalmology, with several key R&D projects underway, including painless cross-linked hyaluronic acid, medical cross-linked chitosan gel, enhanced water-light injection agents, and linear precision cross-linked water-light injection agents [2] Group 2: R&D Focus - Ongoing R&D projects include hydrophilic continuous vision artificial lenses, hydrophobic mold-injected extended depth of focus artificial lenses, intraocular filling biological gels, aqueous permeable PRL, high-permeability scleral lenses, and new high-permeability (DK180) corneal shaping lenses [2]

Core Viewpoint - Haohai Biological Technology has successfully expanded its product lines in the medical aesthetics and ophthalmology sectors, enhancing its global market presence and growth potential [2]. Group 1: Medical Aesthetics - Haohai's subsidiary Bioxis has successfully launched its Cytosial hyaluronic acid product in Europe, South America, and the Middle East, achieving sales in these regions [2]. Group 2: Ophthalmology - The company's core platform Contamac supplies approximately 17 million optical raw materials annually to contact lens and artificial lens manufacturers in over 70 countries worldwide [2]. - The establishment of these platforms is expected to continuously empower the global layout of the company's product lines, opening up broader development opportunities [2].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,740 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,74 ...

截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,740 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,740 | FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動 ...

Core Viewpoint - Haohai Biological Technology Co., Ltd. is experiencing a decline in revenue and net profit, with significant changes in shareholder structure and financing activities [2][3]. Group 1: Financial Performance - For the period from January to September 2025, Haohai Biological reported operating revenue of 1.899 billion yuan, a year-on-year decrease of 8.47% [2]. - The net profit attributable to shareholders for the same period was 305 million yuan, reflecting a year-on-year decline of 10.63% [2]. Group 2: Shareholder and Financing Activities - As of February 2, 2025, the number of shareholders increased to 8,388, representing a 7.44% rise compared to the previous period [2]. - On February 2, 2025, Haohai Biological had a financing balance of 113 million yuan, accounting for 1.28% of its market capitalization, which is above the 50th percentile level over the past year [1]. - The company has cumulatively distributed dividends of 891 million yuan since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Business Overview - Haohai Biological, established on January 24, 2007, and listed on October 30, 2019, focuses on the research, production, and sales of medical devices and pharmaceuticals [1]. - The revenue composition of the company includes 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [1].

上海昊海生物科技股份有限公司 H 股同步公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 12 月 12 日，上海昊海生物科技股份有限公司（以下简称"公司"） 召开第六届董事会第六次会议和第六届董事会独立董事第二次专门会议，审议通 过了《关于购买股权暨与关联人共同投资的议案》，同意公司以自有资金人民币 38,351,487.36 元受让苗九昌、苗春云合计持有的江西瑞济生物工程技术股份有限 公司（以下简称"瑞济生物"）8,466,112 股股份，占瑞济生物总股本的 19.8000% （以下简称"本次交易"）。本次受让股权后将形成与关联人共同投资。本次交 易未涉及与关联人之间发生资金往来或权属转移。具体详见公司于 2025 年 12 月 13 日在上海证券交易所网站（www.sse.com.cn）披露的《上海昊海生物科技股份 有限公司关于购买股权暨与关联人共同投资的公告》（公告编号：2025-050）及 在香港联合交易所网站（www.hkexnews.hk）同步发布的相关 H 股公告。 2026 年 1 月 ...